Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Viral Matters focuses on all aspects of Direct Acting Antivirals (DAA) and Antiretrovirals in development and on the market.
Pages
Search This Blog
About Me
- Chris Barnes
- Redondo Beach, CA, United States
- A 17 year veteran of Medical Affairs and Commercial functions of the biopharma and pharmaceutical industry, with expertise in Hepatitis and HIV. christopherjbarnes10@gmail.com
Posts
Followers
Blog Archive
-
▼
2012
(157)
-
▼
April
(21)
- Canadian Association of Hepatology Nurses (CAHN) s...
- JMP Securites upgrades Idenix stock on HCV pipelin...
- Duke University program integrates Hepatitis C and...
- J&J open to partnering with Vertex in HCV drug dev...
- 'The Street' grades the HCV players post-EASL...
- Presidio Pharmaceuticals announce new HCV pan-geno...
- Boehringer Ingelheim presents interferon-free SOUN...
- New York Times on GS-7977 + daclatasvir combo - wi...
- Gilead interim ELECTRON and QUANTUM SVR4 data...
- Bristol-Myers Squibb and Medivir/J&J expand on Dir...
- NPR: The Race To Create The Best Antiviral Drugs
- The emerging role of the Infectious Disease physic...
- Seeking Alpha - Achillion Will Soar Higher On New ...
- Bloomberg BusinessWeek on Gilead's GS-7977 and cri...
- Chronic HCV associated with high comorbidities in ...
- Merck and Codex go "green" with new production pro...
- BMS-Gilead EASL data leak spurs speculation...
- The Street - "Winners, Losers From EASL Hep C Data...
- Abbott Laboratories releases data on PILOT & CO-PI...
- EASL 2012 International Liver Conference abstracts...
- Post-Scripps Conference Download "New Treatments i...
-
▼
April
(21)
No comments:
Post a Comment